NCT04270981View on ClinicalTrials.gov

ADME Study of Acoziborole in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 5, 2020

Primary Completion Date

July 8, 2020

Study Completion Date

July 8, 2020

Conditions
Trypanosomiases, African
Interventions
DRUG

[14C]-acoziborole capsule, 240 mg containing NMT 9.25 kBq (250 nCi) 14C

960 mg (4 × 240 mg capsules)of acoziborole in oral and fasted condition

Trial Locations (1)

Unknown

Quotient Sciences, Nottingham

All Listed Sponsors
lead

Drugs for Neglected Diseases

OTHER

NCT04270981 - ADME Study of Acoziborole in Healthy Subjects | Biotech Hunter | Biotech Hunter